These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Seymour JF; Byrd JC; Ghia P; Kater AP; Chanan-Khan A; Furman RR; O'Brien S; Brown JR; Munir T; Mato A; Stilgenbauer S; Bajwa N; Miranda P; Higgins K; John E; de Borja M; Jurczak W; Woyach JA Blood; 2023 Aug; 142(8):687-699. PubMed ID: 37390310 [TBL] [Abstract][Full Text] [Related]
5. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis. Nunes RAB; Avezum Á; de Oliveira Marques M; Baiocchi OCCG; Bachour P Ann Hematol; 2024 Aug; ():. PubMed ID: 39153144 [TBL] [Abstract][Full Text] [Related]
6. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Woyach JA; Jones D; Jurczak W; Robak T; Illés Á; Kater AP; Ghia P; Byrd JC; Seymour JF; Long S; Mohamed N; Benrashid S; Lai TH; De Jesus G; Lai R; de Bruin G; Rule S; Munugalavadla V Blood; 2024 Sep; 144(10):1061-1068. PubMed ID: 38754046 [TBL] [Abstract][Full Text] [Related]
7. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844 [TBL] [Abstract][Full Text] [Related]
9. An update on acalabrutinib to treat chronic lymphocytic leukemia. Blackmon A; O'Brien S Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530 [TBL] [Abstract][Full Text] [Related]
10. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. Khan Y; O'Brien S Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956 [TBL] [Abstract][Full Text] [Related]
12. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Wolska-Washer A; Robak T Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194 [TBL] [Abstract][Full Text] [Related]
13. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Byrd JC; Hillmen P; Ghia P; Kater AP; Chanan-Khan A; Furman RR; O'Brien S; Yenerel MN; Illés A; Kay N; Garcia-Marco JA; Mato A; Pinilla-Ibarz J; Seymour JF; Lepretre S; Stilgenbauer S; Robak T; Rothbaum W; Izumi R; Hamdy A; Patel P; Higgins K; Sohoni S; Jurczak W J Clin Oncol; 2021 Nov; 39(31):3441-3452. PubMed ID: 34310172 [TBL] [Abstract][Full Text] [Related]
14. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093 [TBL] [Abstract][Full Text] [Related]
15. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death. Boriani G; Menna P; Morgagni R; Minotti G; Vitolo M Chemotherapy; 2023; 68(2):61-72. PubMed ID: 36366814 [TBL] [Abstract][Full Text] [Related]
16. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. Miao Y; Xu W; Li J Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396 [TBL] [Abstract][Full Text] [Related]
17. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. Egyed M; Lueff S; Borbely J; Illes A Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644 [TBL] [Abstract][Full Text] [Related]
18. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679 [No Abstract] [Full Text] [Related]
19. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Furman RR; Byrd JC; Owen RG; O'Brien SM; Brown JR; Hillmen P; Stephens DM; Chernyukhin N; Lezhava T; Hamdy AM; Izumi R; Patel P; Baek M; Christian B; Dyer MJS; Streetly MJ; Sun C; Rule S; Wang M; Ghia P; Jurczak W; Pagel JM; Sharman JP Leukemia; 2021 Nov; 35(11):3201-3211. PubMed ID: 33907299 [TBL] [Abstract][Full Text] [Related]
20. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Strati P; Coleman M; Champion R; Ma S; Patti C; Levy MY; Lossos IS; Geethakumari PR; Lam S; Calvo R; Higgins K; Budde LE Br J Haematol; 2022 Oct; 199(1):76-85. PubMed ID: 35861370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]